TBPH Q3 2019 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M-3.2% YoY

Gross Profit

-$40M-318.5% margin

Operating Income

-$65M-524.7% margin

Net Income

-$58M-470.2% margin

EPS (Diluted)

$-1.05

QoQ Revenue Growth

-52.5%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$45M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$445M

Total Liabilities

$628M

Stockholders' Equity

-$183M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$13M	-3.2%
Gross Profit	-$40M	$12M	-426.2%
Operating Income	-$65M	-$62M	-4.4%
Net Income	-$58M	-$59M	+1.7%

Revenue Segments

Collaborative Arrangement Revenue

$9M71%

Co Promote Agreement

$4M29%